17-Mar-2025
Exeliom Biosciences
Exeliom Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapies in immuno-inflammation and immuno-oncology. Their work focuses on targeting the NOD2 pathway, with the goal of reprogramming the immune system using precision microbiome effectors.
Since March 2024, ALA has worked with Exeliom to support their efforts through the creation and management of press releases, as well as regular content development for LinkedIn.
Editor Details
-
Company:
- Andrew Lloyd Associates
- Website:
Last Updated: 17-Mar-2025
